Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sensei Biotherapeutics Inc SNSE

Healthcare Biotechnology
Sensei Biotherapeutics, Inc. is a clinical-stage immuno-oncology company, which is focused on the discovery and development of therapeutics for cancer patients. Through its Tumor Microenvironment Activated biologics (TMAb) platform, the Company develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor... see more

Recent & Breaking News (NDAQ:SNSE)

Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 3 days ago

Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences

GlobeNewswire October 29, 2024

Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference

GlobeNewswire September 4, 2024

Sensei Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire September 4, 2024

Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire August 6, 2024

Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 30, 2024

Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101

GlobeNewswire May 23, 2024

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire May 9, 2024

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

GlobeNewswire April 24, 2024

Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference

GlobeNewswire April 9, 2024

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

GlobeNewswire April 4, 2024

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

GlobeNewswire March 22, 2024

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

GlobeNewswire March 6, 2024

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

GlobeNewswire February 28, 2024

Sensei Biotherapeutics to Present at Upcoming Conferences

GlobeNewswire February 7, 2024

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

GlobeNewswire January 4, 2024

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

GlobeNewswire November 7, 2023

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

GlobeNewswire November 3, 2023

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

GlobeNewswire November 1, 2023

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

GlobeNewswire October 25, 2023